Three-Year Experience with Risedronate Therapy for Patients with an Increased Fracture Risk: Assessment of Proximal Femoral Bone Density and Geometry by DXA

Author： Takakuwa Masayuki  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.32, Iss.2, 2012-02, pp. : 121-129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Contraceptives, bone mineral density and fracture risk

By  

Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Increased fracture risk with androgen-deprivation therapy

By  

Reactions Weekly, Vol. 1, Iss. 1035, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Evaluation of the Effect of 4 Months of Risedronate Therapy on Femoral Strength Using Femoral Strength Analysis Tools

By Takakuwa M   Otsuka K   Konishi M   Itabashi K  

The Journal of International Medical Research, Vol. 37, Iss. 6, 2009-11 ,pp. : 1972-1981

Field House Publishing

Access to resources Recommend Favorite

Psychotropic medications: increased risk of fracture?

By  

Reactions Weekly, Vol. 1, Iss. 1137, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Three-year Experience with Alendronate Treatment in Postmenopausal Osteoporotic Japanese Women with or without Renal Dysfunction: A Retrospective Study

By Iwamoto Jun  

Drugs & Aging, Vol. 29, Iss. 2, 2012-02 ,pp. : 133-142

Adis International

Access to resources Recommend Favorite